Refine by
Cancer Antigen Articles & Analysis
43 articles found
In the field of vaccine development, peptide vaccines, as an emerging vaccine platform, have gradually become the focus of research due to their advantages such as high safety, strong targeting, and customizability. However, despite the great potential shown by peptide vaccines, stability and immunogenicity remain two major challenges in their application process. Issues such as peptide ...
Traditional cancer treatments do not possess the necessary precision to target only cancer cells which leads to poor treatment results and harmful side effects. ...
In recent years, the fight against cancer has seen significant advances, particularly with the emergence of targeted therapy. ...
Antibody-Drug Conjugates (ADCs) represent a groundbreaking advancement in targeted cancer therapy, combining the specificity of antibodies with the potency of cytotoxic drugs. ...
This bionic nanostructure has proven effective for drug delivery, detoxification, photothermal treatment, imaging, cancer diagnosis, immune surveillance, vaccine design, etc. This paper presents the most recent research advances of cell membrane nanodrug delivery systems for bionic medicine. ...
They are adept at identifying and destroying infected or cancerous cells. However, their natural capacity may not always be sufficient to combat complex diseases. ...
Committed to pushing the boundaries of cancer research, Alfa Cytology collaborates closely with the scientific community, constantly exploring new diagnostic and therapeutic frontiers. ...
Ensure Specificity and TargetingThe main advantage of ADC lies in its high specificity for specific cancer cell surface antigens. Biological activity analysis can verify whether ADC can accurately identify and bind to target antigens. ...
To grasp how cancer vaccines work, it is pivotal to understand two fundamental components of the immune system: antigens and antibodies. ...
Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. ...
ByTempus
Poly(lactic-co-glycolic acid) (PLGA) is a functional polymer organic compound randomly polymerized by lactic acid (PLA) and glycolic acid (PGA). It has been approved by the U.S. Food and Drug Administration It is certified by the Food and Drug Administration (FDA) and is a copolymer material available on the market. PLGA has good biocompatibility, biodegradability, mechanical strength, good ...
The antibody component specifically targets surface antigens on specific cancer cells, while the drug component is responsible for killing these bound cancer cells. ...
Nanobodies are the smallest functional single-domain antibodies known to be able to stably bind to antigens, and have unique structural and functional advantages. The molecular weight of nanobodies is only 12-15 kDa, which retains the antigen binding ability of traditional antibodies. ...
Bispecific antibodies have two antigen-binding arms, one of which binds to the target antigen and the other to the labeled antigen on the effector cells. ...
In humans, MHC is referred to as human leukocyte antigen (HLA).Assessing Epitope Antigenicity and ImmunogenicityThe predicted immunogenicity of peptide epitopes can be analyzed through two in vivo methods: 1) in vivo immunogenicity analysis using HLA transgenic mice; 2) antigenicity testing using human antigen-presenting cells ...
Oncolytic Viruses are wrought using an array of techniques, each technique contingent on the virus strain and the cancer form it targets. It is essential to curate a virus capable of adeptly identifying and effacing cancer cells. ...
Antibody-drug conjugates (ADCs), as emerging anticancer drugs, can deliver highly cytotoxic molecules directly to cancer cells to kill them. ADC is a monoclonal antibody covalently bound to cytotoxic chemical substances (payload) through linker. ...
In addition to its indirect effects, TSLP can directly act on CD4+ T cells, aiding in their proliferation, differentiation, and response to antigens[3]. TSLP and cancer New functions of TSLP have been discovered in the induction and progression of various tumors, including solid tumors such as breast, colon, and pancreatic cancers, as well as ...
Considering that targets play a key role in delivering drugs to cancer cells, it is important to develop new targets or ADCs to expand new indications and gain a larger market space. ...
Antibodies are the precise guidance components of ADCs. In theory, molecules that bring effector molecules to the surface of tumor cells can play the role of antibody guidance The choice of antibody for ADC drugs depends on the target of the disease. Targets can be divided into tumor-specific antigens (TSA) and tumor-associated antigens (TAA) according to their expression. Antigens that are only ...